Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCommunity Health Plan Washington genetic testing C…
    Ask Trek AI about this page
    ModifiedCommunity Health Plan WashingtonPolicy N/A

    General Approach to Genetic and Molecular Testing (Genetic Testing: General Approach)

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and coverage approach for germline and somatic genetic/molecular tests (familial variant, carrier screening, single- and multi-gene panels, tumor biomarker and algorithmic tests) including documentation, lab accreditation, counseling, and prior authorization expectations.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGeneral Approach to Genetic and Molecular Testing
    Policy CodePolicy N/A
    Change TypeConsolidation and criteria updates
    Effective DateN/A
    Last ReviewNov 1, 2024
    Next Review DateNov 1, 2025
    Key ActionDocument required clinical documentation demonstrating the member meets test-specific criteria and verify testing in a CLIA-approved laboratory when applicable.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added 'General Tumor Biomarker Analysis', 'Oncology Algorithmic Tests', and 'Other Tests' sections to the policy.

    Updated criteria assessing for clinical validity and utility across multiple test categories (single gene/multigene panels, tumor biomarker analysis, oncology algorithmic tests, other tests).

    Updated definition of targeted prenatal screening to include full gene sequencing or targeted mutation analysis for pathogenic/likely pathogenic variants.

    Removed age restriction for adult-onset tests when clinical features of the condition are present.

    multipletypes of testing addressed
    CLIACLIA requirement
    +3policy additions
    prenataldefinition updated
    Semi-annualreview frequency
    V1.2025version

    Coverage and Medical Necessity Criteria

    Known Familial Variant Analysis — Medically Necessary

    Targeted mutation analysis for a known familial variant is medically necessary when ALL of the following are met:

    Known familial variant medical necessity: A. The member/enrollee is 18 years or older if the condition is adult-onset; AND B. The member/enrollee has a close relative with a known pathogenic or likely pathogenic (P/LP) variant causing the condition; AND C. An association between the gene and disease has been established.

    Targeted mutation analysis for a known familial variant of uncertain significance (VUS) is investigational; targeted analysis for other non-specified indications is investigational.

    Targeted Carrier Screening — Medically Necessary

    Carrier screening via full gene sequencing or targeted mutation analysis may be medically necessary when ALL of the following are met:

    Carrier screening medical necessity: A. The member/enrollee is considering pregnancy or is currently pregnant; AND B. The genetic disorder is an autosomal recessive condition with childhood onset; AND C. One of the following: (1) the member/enrollee has a close relative with a known pathogenic or likely pathogenic variant associated with the disorder, OR (2) the member/enrollee's reproductive partner is a carrier for the genetic disorder, OR (3) the member/enrollee or reproductive partner are members of a population with a carrier rate >= 1% for the condition, OR (4) the member/enrollee or the member's reproductive partner has a first- or second-degree relative affected with the genetic disorder.

    Carrier screening for other indications is considered investigational.

    Single Gene or Multigene Panel Analysis — Medically Necessary

    Single-gene or multigene testing may be medically necessary when ALL of the following are met:

    Single/multigene panel medical necessity: A. The member/enrollee displays clinical features of the suspected genetic condition; AND B. The diagnosis remains uncertain after appropriate clinical evaluation and other standard laboratory tests/imaging have been performed; AND C. The test has clinical validity (accurately determines diagnostic, prognostic, or clinical information for the disease); AND D. The test has clinical utility demonstrated by at least one of: (1) determines if a therapeutic intervention is effective or harmful, OR (2) directly impacts clinical management, OR (3) determines prognosis, OR (4) provides or refines estimates of natural history, recurrence risk, or predicted course; AND E. There is no known familial P/LP variant for which targeted testing would be more appropriate; AND F. Non-genetic causes for the clinical features have been ruled out; AND G. An association between the gene(s)/panel and the disease has been established.

    Genetic testing via single-gene or multigene panel analysis is investigational for all other indications.

    Tumor Biomarker Analysis — Medically Necessary

    Tumor biomarker analysis is medically necessary when the following criteria are met for the respective context:

    Prenatal diagnostic (moved into tumor biomarker section for policy consolidation): I. At least one biological parent has a known pathogenic variant for an autosomal dominant condition, OR both biological parents are known carriers of an autosomal recessive condition, OR one biological parent is suspected or known to be a carrier of an X-linked condition, OR the member/enrollee has a history of a previous child with a genetic condition and germline mosaicism is suspected; AND II. The natural history of the disease is well-understood with high likelihood of morbidity; AND III. The genetic test has adequate sensitivity and specificity to guide clinical decision-making and residual risk is understood.

    Prenatal diagnosis for adult-onset single-gene disorders via invasive testing (amniocentesis, CVS, PUBS) is not medically necessary; VUS in this context is investigational.

    Tumor biomarker for oncology: A. The member/enrollee has a confirmed neoplasm and/or malignancy; AND B. The test has clinical validity (accurately determines diagnostic, prognostic, or clinical information); AND C. The test has clinical utility demonstrated by at least one of: (1) determines if a therapeutic intervention is effective or harmful, OR (2) directly impacts clinical management, OR (3) determines prognosis, OR (4) provides or refines estimates of natural history, recurrence risk, or predicted course; AND D. Testing is performed in a CLIA-approved laboratory.

    General tumor biomarker analysis is investigational for other indications.

    Oncology Algorithmic Tests — Medically Necessary

    Oncology algorithmic testing is medically necessary when ALL of the following are met:

    Algorithmic testing medical necessity: A. The member/enrollee has a suspected or confirmed neoplasm and/or malignancy; AND B. The test has clinical validity (accurately determines diagnostic, prognostic, or clinical information); AND C. The test has clinical utility demonstrated by at least one of: (1) determines if a therapeutic intervention is effective or harmful, OR (2) directly impacts clinical management, OR (3) determines prognosis, OR (4) provides or refines estimates of natural history, recurrence risk, or predicted course.

    Oncology algorithmic testing is investigational for all other indications; see referenced algorithmic testing policy for test-specific criteria.

    Other Tests — Medically Necessary

    Other genetic/molecular tests are medically necessary when ALL of the following are met:

    Other tests medical necessity: A. The member/enrollee displays relevant clinical features consistent with the intended use of the test; AND B. The test has clinical validity (accurately determines diagnostic, prognostic, or clinical information); AND C. The test has clinical utility demonstrated by at least one of: (1) determines if a therapeutic intervention is effective or harmful, OR (2) directly impacts clinical management, OR (3) determines prognosis, OR (4) provides or refines estimates of natural history, recurrence risk, or predicted course; AND D. Testing is performed in a CLIA-approved laboratory.

    Other tests are investigational for indications not meeting these criteria.

    General coverage criteria — analytic validity, clinical validity, clinical utility

    Covered when tests demonstrate appropriate analytic validity, clinical validity, and clinical utility and when pretest evaluation and counseling support testing.

    General criteria: Test demonstrates sufficient analytic validity, clinical validity, and clinical utility as assessed by the policy and referenced guidelines/frameworks (e.g., ACMG, NCCN, CDC ACCE Model, Hayes et al.).

    Policy revisions emphasize clinical validity and utility across test categories.

    Oncology algorithmic tests coverage: Covered for suspected or confirmed neoplasm when analytical performance and evidence of clinical utility in guiding therapy or prognosis are adequate and aligned with NCCN and policy criteria.

    Policy expanded to include suspected neoplasm as an indication.

    Prenatal and targeted testing guidance: Targeted prenatal screening includes full gene sequencing or targeted mutation analysis for a pathogenic/likely pathogenic variant; prenatal testing for adult-onset conditions is discouraged unless pregnancy or childhood management would be affected and appropriate counseling is provided.

    Prenatal diagnosis content was moved into this policy and definitions were updated.

    General criteria sources

    Policy references and professional guidance that underpin the coverage criteria:

    References and guideline basis: Coverage approach is informed by professional guidelines and position statements (ACOG, NSGC, ACMG, NCCN), the CDC ACCE Model, and key literature on clinical validity and utility (e.g., Burke et al., Hayes et al.).

    See policy reference list for full citations.

    Prenatal diagnosis by invasive procedures (amniocentesis, chorionic villus sampling, or percutaneous umbilical blood sampling) for adult-onset single-gene disorders is not medically necessary when performed solely for prediction of conditions that manifest in adulthood. This policy designates invasive prenatal single-gene testing for adult-onset disorders (for example, hereditary cancer syndromes such as BRCA1/2) as not medically necessary and considers testing for variants of uncertain significance investigational.

    The National Society of Genetic Counselors (NSGC) recommends against prenatal genetic testing for known adult-onset conditions when the result will not affect pregnancy management or childhood care. Prospective parents should receive pre-test genetic counseling to discuss natural history, available interventions, ethical considerations (including potential impact on a child’s future autonomy), and the limits and implications of testing prior to pursuing prenatal testing for adult-onset conditions.

    Coverage and payment for genetic and molecular testing are governed by the member’s specific coverage documents and applicable state and federal requirements. Benefits are administered according to the terms, conditions, exclusions, and limitations of the evidence of coverage, certificate of coverage, policy, contract, and Health Plan administrative procedures; these plan-level rules may restrict coverage even when policy criteria are met.

    For example, this policy explicitly lists prenatal diagnosis for single-gene disorders via amniocentesis, chorionic villus sampling, or percutaneous umbilical blood sampling as not medically necessary when the indication is an adult-onset condition (e.g., hereditary cancer syndromes). Variants of uncertain significance detected in the familial context are considered investigational and are not appropriate indications for invasive prenatal diagnosis.

    The policy discourages several uses of genetic testing that lack clinical justification: targeted analysis of a familial variant of uncertain significance (VUS) is investigational; carrier screening performed outside the defined reproductive or preconception contexts or without qualifying family or population risk is investigational; and ordering broad single-gene or multigene panels, tumor biomarker tests, or algorithmic tests when the specific clinical validity and clinical utility criteria are not met is considered investigational or not medically necessary.

    Predictive genetic testing of minors for adult-onset conditions should generally be deferred when the result will not affect medical management during childhood. Professional guidance supports postponing predictive testing until the individual can participate in decision-making, unless an intervention begun in childhood would reduce morbidity or mortality.

    Denials may be issued when requested testing does not meet the Health Plan’s medical necessity criteria or when the request conflicts with plan terms, exclusions, or applicable coverage documents. Providers should document clinical indications, counseling, and rationale showing how the requested test meets the policy’s clinical validity and clinical utility requirements to reduce the risk of denial.

    Examples of Covered Indications

    Covered broad test categories – clinical validity and utility requirement

    Covered broad test categories when clinical validity and clinical utility are demonstrated:

    Covered broad test categories: Known familial P/LP variant testing (targeted), carrier screening in pregnancy or preconception for specified conditions, diagnostic single-gene or multigene panels for unresolved diagnostic cases, tumor biomarker analysis and oncology algorithmic testing for confirmed or suspected malignancy — each when the test meets analytic validity, clinical validity, and clinical utility criteria.

    See respective sections for specific eligibility and documentation requirements.

    Diagnostic evaluation indications — when genetic diagnosis informs care

    Diagnostic evaluation indications where genetic testing may be medically necessary:

    Diagnostic evaluation indications: Genetic testing is indicated when a definitive genetic diagnosis will inform causality, prognosis, or treatment; for newborn screening conditions recommended by advisory committees; in patients with complex disorders (e.g., autism, intellectual disability) or rare disorders; and when discovery of actionable secondary findings would affect management.

    Eligibility and Ordering Requirements

    For targeted familial variant analysis to be eligible, the close relative must have a documented pathogenic or likely pathogenic (P/LP) variant in the gene of interest. The policy requires that the familial P/LP variant be present in a first-, second-, or third-degree relative to support targeted testing, and specifies that targeted analysis for a familial VUS is investigational.

    Eligibility for targeted familial variant testing requires documentation that the family member’s variant is classified as pathogenic or likely pathogenic and that an association between the gene and the disease has been established. The member’s relationship to the affected relative (e.g., first-, second-, or third-degree) should be clearly documented in the clinical record.

    Testing requests for targeted familial variant analysis must include evidence of the known familial P/LP variant (for example, prior laboratory report confirming the variant and classification). Absent documentation of a familial P/LP variant, targeted testing is not supported.

    Top-level eligibility principles require that any genetic test ordered demonstrate adequate analytic validity, clinical validity, and clinical utility. Tests should be ordered only when pretest evaluation, counseling, and documentation support that the result will influence clinical management or reproductive decision-making.

    When a known familial P/LP variant exists, the policy favors targeted variant analysis as the preferred first-line test. Ordering broader single-gene or multigene panels in this context requires explicit justification demonstrating why targeted testing would be insufficient and how broader testing meets clinical validity and utility criteria.

    If no known familial P/LP variant is documented, single-gene or multigene panel testing may be appropriate when the member displays clinical features of the suspected condition, non-genetic causes have been excluded, and testing meets the policy’s clinical validity and utility standards. Panel testing should be guided by clinical indication and not performed routinely when a targeted familial test is available.

    Provider Responsibilities and Operational Requirements

    Prior Authorization

    Verify CLIA lab accreditation and test validity

    Testing for tumor biomarker analysis and other tests designated as medically necessary must be performed in a Clinical Laboratory Improvement Amendments (CLIA)–approved laboratory; prior authorization processes should verify laboratory accreditation and that the test meets clinical validity and clinical utility criteria.

    • CLIA requirement applies to tumor biomarker and other tests: “Testing is being performed in a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory.”
    • Prior auth should verify laboratory accreditation and that the test meets clinical validity/utility standards described in the policy.
    Prior Authorization

    Expect updated prior authorization expectations after policy changes

    Policy revisions and consolidation emphasize clinical validity and clinical utility across test categories; providers should expect that prior authorization criteria and documentation expectations may change and should document clinical features and rationale when ordering tests.

    Investigational or Not Medically Necessary Services

    Targeted mutation analysis for a known familial variant of uncertain significance (VUS) is considered investigational and is not covered. Other investigational contexts include testing performed without meeting the stated clinical validity and clinical utility criteria for the indicated test class.

    The policy identifies multiple investigational or not-covered scenarios that overlap: familial VUS testing, carrier screening outside defined reproductive contexts or population risk, and panels or tumor/algorithmic tests ordered without evidence of clinical validity or utility are considered investigational or not medically necessary.

    Investigational determinations apply when tests lack sufficient evidence of analytic performance, clinical validity, or clinical utility, or when clinical documentation does not support that results would alter management or reproductive decisions.

    Requests for testing in investigational or not-covered categories will generally be denied; providers should refer to the policy’s defined criteria and provide documentation when asserting medical necessity in atypical cases.

    Coverage determinations may also be constrained by National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and other applicable federal or state policies. Certain tests or indications may be excluded from coverage under these external determinations even if the plan’s clinical criteria would otherwise be met.

    Definitions and Terminology

    Germline vs Somatic variants — definitions for germline and somatic variants
    Germline variantInherited alteration in egg or sperm integrated into every cell of the body and potentially passed to offspring.
    Somatic variantGenetic alteration that occurs in a cell or group of cells (e.g., tumor) and is not inherited or transmitted to offspring.
    Clinical relevanceGermline testing informs inherited risk, family counseling, and reproductive planning; somatic testing informs tumor-specific therapy and prognosis.
    Clinical validity and clinical utility — definition and explanation
    Clinical validityThe accuracy with which a test identifies a clinical condition, measured by sensitivity, specificity, positive predictive value, and negative predictive value.
    Clinical utility

    Background

    Genetic testing identifies both germline and somatic variants. Germline variants are inherited changes present in every cell and passed to offspring, whereas somatic variants arise in a cell or group of cells (for example, within a tumor) and are not inherited. The policy covers a range of test types, from targeted familial variant analysis and carrier screening to single-gene and multigene panels, tumor biomarker analysis, and algorithmic oncology tests, and requires evidence of analytic validity, clinical validity, and clinical utility to support medical necessity.

    Policy Revision History

    2024-11-01policy_reviewLatest

    Policy last reviewed; consolidated test categories and emphasized clinical validity and utility across test classes (added General Tumor Biomarker Analysis, Oncology Algorithmic Tests, and Other Tests).

    2024-04-23revision

    Policy developed and approved; initial consolidation and addition of General Tumor Biomarker Analysis, Oncology Algorithmic Tests, and Other Tests; updated notes and definitions (V1.2024).

    2024-04-24
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGeneral Approach to Genetic and Molecular Testing
    Policy CodePolicy N/A
    Change TypeConsolidation and criteria updates
    Effective DateN/A
    Last ReviewNov 1, 2024
    Next Review DateNov 1, 2025
    Key ActionDocument required clinical documentation demonstrating the member meets test-specific criteria and verify testing in a CLIA-approved laboratory when applicable.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaExamples of Covered IndicationsEligibility and Ordering RequirementsProvider Responsibilities and Operational RequirementsInvestigational or Not Medically Necessary ServicesDefinitions and TerminologyBackgroundPolicy Revision History

    Clinical evaluation and uncertainty after standard testing should precede panel testing (see single/multigene criteria).

    Oncology indications — somatic/tumor testing for therapy guidance

    Oncology indications for somatic/tumor testing:

    Oncology indications: Somatic/tumor molecular genetic testing is indicated for patients who are candidates for anti-cancer therapy to identify actionable tumor changes; testing should have clinical validity and utility (e.g., determine therapy selection, prognosis, or management).

    Criteria align with NCCN guidance; tumor testing should be performed in CLIA-approved laboratories.

    Prenatal assessment — aneuploidy and targeted prenatal diagnosis with counseling

    Prenatal assessment and prerequisites for targeted prenatal diagnosis:

    Prenatal assessment indications: Prenatal assessment for aneuploidy and targeted prenatal diagnosis is indicated when risk factors are present (advanced parental age, prior child with structural defect or aneuploidy, ultrasound anomalies, parental carrier status); AND pretest counseling is required to discuss test performance and implications.

    Prenatal testing for adult-onset conditions is generally not recommended unless pregnancy or childhood management would be affected; confirmation in an affected child may be required to ensure informative testing for recurrence risk.

    Prenatal diagnostic testing and carrier screening — cited ACOG and NSGC guidance

    Prenatal diagnostic testing and carrier screening are informed by professional guidance:

    Prenatal diagnostic and carrier screening guidance: Policy cites ACOG practice bulletins and NSGC position statements recommending universal offer of aneuploidy assessment, targeted carrier screening in appropriate populations, and counseling prior to prenatal testing; NSGC advises against prenatal testing for adult-onset conditions when management will not be affected without thorough counseling.

    See referenced ACOG and NSGC documents for detailed recommendations and counseling expectations.

    Documentation supporting eligibility must include the member’s clinical presentation, family history specifying the relative with the P/LP variant, and prior testing results if available. For carrier screening, evidence of pregnancy or reproductive planning and population or family risk (for example, carrier frequency >=1% in the population) should be provided when applicable.

    When deciding between targeted and broader testing approaches, providers must consider analytic and clinical validity, the gene content of panels, and the potential for variants of uncertain significance; multigene panels are supported when clinically warranted and when the panel’s validity and utility are clear.

  1. Policy updates added and reorganized tumor biomarker, oncology algorithmic, and other test categories and emphasized clinical validity/utility.
  2. Document clinical features and rationale to support prior authorization decisions.
  3. Prior Authorization

    Check plan-level prior authorization requirements

    Prior authorization requirements for genetic and molecular testing are governed by the Health Plan's administrative policies and member coverage documents; providers should check plan-level procedures before ordering tests.

    • Coverage decisions and administration of benefits are subject to terms, exclusions, and limitations of coverage documents and Health Plan procedures.
    Step Therapy

    Prefer targeted familial variant testing first

    When a known familial pathogenic or likely pathogenic (P/LP) variant exists in a relative, targeted familial variant analysis is preferred over broader single‑gene or multigene panel testing unless broader testing is clinically indicated.

    • Known familial variant testing criteria: targeted analysis medically necessary when a close relative has a known P/LP variant.
    • Panels are only appropriate when no known familial P/LP variant exists or broader testing is otherwise clinically indicated.
    Documentation Required

    Confirm affected-child molecular diagnosis for prenatal recurrence testing

    When ordering prenatal recurrence testing, confirm molecular diagnosis in the affected child when available to ensure informative testing for subsequent pregnancies and document the need for testing.

    • A diagnosis established by molecular testing of the affected child is usually necessary to ensure recurrence testing is informative and risk assessment is accurate.
    • Pretest counseling per ACOG should be provided and documented.
    Billing Rule

    Follow plan-specific administrative and coverage rules

    Coverage is subject to the Health Plan's administrative policies and member coverage documents; providers must follow plan-level procedures and check for any plan-specific limitations or exclusions when ordering and billing tests.

    • The policy guide is not a contract or guarantee of payment; coverage and benefit administration are subject to coverage documents and applicable legal/regulatory requirements.
    Documentation Required

    Provide required clinical documentation supporting medical necessity

    Clinical documentation must demonstrate that the member meets the specific criteria for the test class (for example: age and family variant status for targeted familial variant analysis; pregnancy/reproductive status for carrier screening; confirmed neoplasm and CLIA lab for tumor biomarker testing).

    • Document age or adult‑onset condition considerations for familial variant testing.
    • Document pregnancy/reproductive intent and indication for carrier screening.
    • Document confirmed neoplasm and CLIA lab testing for tumor biomarker analysis.
    • Document that the test has demonstrated clinical validity and clinical utility per policy criteria.
    Documentation Required

    Perform and document pretest counseling and informed consent

    Provide pretest counseling and informed consent that discusses test sensitivity and specificity, potential results (positive, negative, indeterminate), residual risk, implications for management and family, and the patient’s option to decline testing.

    • ACOG Committee Opinion No. 693: discuss test performance, types of potential results, risks, limitations, and benefits before testing.
    • Document that counseling was provided and that the patient had the option to decline testing.
    Billing Rule

    Follow applicable coverage documents and legal requirements

    Providers must follow applicable coverage documents (evidence of coverage, certificate of coverage, policy/contract) and state/federal requirements when submitting claims for genetic and molecular testing.

    • Coverage decisions and benefit administration are subject to all terms, conditions, exclusions, and limitations of the coverage documents.
    Denial Risk

    Denial risk when requests do not meet medical necessity criteria

    Requests that do not meet the policy's stated medical necessity criteria for the specific test class may be denied; examples include ordering targeted familial variant analysis without a close relative with a known P/LP variant or ordering carrier screening outside specified reproductive contexts.

    • Targeted familial VUS testing is investigational and may be denied.
    • Carrier screening outside pregnancy/reproductive planning or population‑risk criteria is investigational.
    • Single/multi‑gene panels ordered without meeting diagnostic uncertainty and prior evaluation criteria risk denial.
    • Tumor biomarker tests without a confirmed neoplasm or without CLIA lab testing risk denial.
    Denial Risk

    Non‑coverage risk for tests without demonstrated clinical validity/utility

    Tests that lack demonstrated clinical validity and clinical utility as required by the policy are subject to non‑coverage decisions; providers should document evidence that the requested test meets these standards.

    • Policy revisions emphasize assessment of analytic validity, clinical validity, and clinical utility before coverage is allowed.
    • Document how the test will determine therapy, impact management, determine prognosis, or refine natural history/recurrence risk.
    Note

    Coverage is subject to member coverage document terms

    Coverage decisions and benefit administration are governed by the terms, conditions, exclusions, and limitations of the member’s coverage documents; failure to meet those terms may result in denial or nonpayment.

    • This policy guides medical necessity determinations but does not guarantee payment; follow the member’s evidence of coverage and plan contract.
    Note

    Recommend genetic counseling by qualified provider

    Genetic counseling is recommended for patients at risk for inherited disorders and those undergoing genetic testing; counseling should be performed by an individual with expertise in genetic medicine and testing methods.

    • Counseling should address test performance, potential results, residual risk, and implications for the patient and family.
    • ACOG Committee Opinion No. 693 is referenced for counseling expectations.
    Note

    Recommend counseling for carrier and prenatal testing

    Genetic counseling is recommended for patients undergoing carrier screening, prenatal testing, or diagnostic genetic evaluation; counseling should be documented and include discussion of implications and follow‑up.

    • Carrier screening and counseling ideally occur before pregnancy; counseling offered when carriers are identified.
    • Document counseling provided and any decisions made by the patient.
    Documentation Required

    Document counseling for patients undergoing genetic testing

    Genetic counseling is recommended across multiple sections of the policy for patients at risk and those undergoing testing; document counseling and involve genetics experts when appropriate.

    • Pretest counseling is recommended for all genetic testing and should be documented.
    • Refer to professional guidance (ACOG, NSGC) as appropriate.
    Note

    Use ACOG and professional guidance for counseling content

    See ACOG Committee Opinion No. 693 and other professional guidance for counseling content and documentation expectations when ordering prenatal and other genetic tests.

    • ACOG states that expectations regarding test performance and types of potential results should be discussed before testing and that patients may decline testing after counseling.
    • Use referenced guidance to structure counseling and consent documentation.
    Note

    No specific specialty restrictions—document clinical indication

    The policy does not impose specific specialty restrictions on ordering clinicians within these chunks; however, ordering clinicians must document the clinical indication and meet the policy’s documentation requirements.

    • No explicit provider specialty limitations are specified in these sections—document clinical evaluation, prior testing, and rationale.
    • Follow plan-level administrative policies for any additional ordering requirements.
    Note

    Follow plan-level rules for any ordering provider qualifications

    No explicit ordering provider restrictions are defined in these policy excerpts; providers should follow plan-level administrative policies and applicable state or federal regulations when ordering tests.

    • Adhere to coverage documents and Health Plan procedures for any provider qualifications required for authorization or payment.
    Note

    No explicit ordering provider restrictions—adhere to plan policies

    There are no explicit provider‑specialty requirements in these sections; follow applicable Health Plan administrative policies and document the clinical indication and supporting evidence when ordering genetic tests.

    • Ensure documentation demonstrates the member meets the specific test criteria even if the policy does not restrict ordering to certain specialties.
    The risks and benefits resulting from use of a genetic test, i.e., whether testing and subsequent interventions lead to improved health outcomes or meaningful changes in management.
    Use in decision-makingClinical validity informs how reliably a test diagnoses a condition; clinical utility determines whether the test changes therapy, management, prognosis, or outcomes.
    Algorithmic test — definition of algorithmic/combined biomarker-clinical tests
    Algorithmic (combined biomarker-clinical) testA test that combines biomarkers and clinical data into an algorithm to generate disease risk assessment, prognostic results, or treatment recommendations (e.g., gene expression profiling, multianalyte assays with algorithmic analysis).
    Common methodologiesTypical methodologies include gene expression profiling (multiple mRNA), multimarker serum analysis, single-nucleotide variant testing, plasma proteomic analysis, and incorporation of clinical data into outputs.
    Clinical contextMedically necessary when performed for suspected or confirmed neoplasm and when the test demonstrates clinical validity and clinical utility in guiding therapy, management, or prognosis.
    ACCE Model — definition of the ACCE framework for test evaluation
    ACCE ModelFramework evaluating Analytic Validity, Clinical Validity, Clinical Utility, and Ethical/Legal/Social Implications using a standardized set of 44 targeted questions for test evaluation.
    PurposeProvides a structured process to assess disorder, test performance, clinical scenarios, and associated ethical, legal, and social issues before adopting testing.
    ResourcesDetailed ACCE questions and guidance are available from the CDC's Office of Public Health Genomics website.
    Multi-gene panel guidance — NSGC position on panels and provider evaluation expectations
    NSGC position on multi-gene panelsNSGC supports the use of multi-gene panels when clinically warranted and appropriately applied, emphasizing comprehensive evaluation before ordering.
    Provider evaluation expectationsProviders should evaluate analytic and clinical validity, clinical utility, gene content of the panel, sequencing and informatics limitations, and variant interpretation/reporting practices prior to ordering.
    Role of expertsNSGC highlights the value of genetic counselors and experts to educate stakeholders, mitigate patient harm, and limit unnecessary costs when panels magnify testing complexities.
    Clinical utility — elaboration on clinical utility concept
    Clinical utility conceptClinical utility addresses whether testing and any subsequent interventions lead to improved health outcomes and what risks result from testing.
    Individual vs societal utilityClinical utility can be assessed for individual patient management (diagnosis, therapy, prognosis) and for societal benefits (research accrual, population health), as noted in referenced literature and professional statements.
    Evidence considerationsDetermination of clinical utility requires demonstration that test results directly impact therapy choice, clinical management, prognosis, or recurrence risk estimates.
    revision

    Minor expansions and rewording to align criteria with guidelines (added 'suspected neoplasm' to oncology algorithmic tests), moved prenatal/carrier criteria into this policy, updated definition of targeted carrier screening, and removed age restriction for adult-onset tests when clinical features present.